Skip to content
value.today

Aeolus Pharmaceuticals, Inc.

Formerly INCARA PHARMACEUTICALS CORP, INCARA INC

Total raised
$16 M
5 rounds on record
Latest round
$7 M
Dec 2015
First round on record
Mar 2009
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aeolus Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2015$7 MNo. 5$2 to $10 million

Aeolus Pharmaceuticals, Inc.: Raise no. 5, Dec 2015

Investors in this round

43 investors had bought by the notice of Dec 18, 2015: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$194,735
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Day · Executive Officer
  • David C. Cavalier · Executive Officer, Director
  • JOHN McMANUS · Executive Officer
  • Ken A. Bright · Executive Officer
  • Amit A. Kumar · Director
  • Chris A. Rallis · Director
  • Jeffrey A. Scott · Director
  • John M. Clerici · Director
  • John M. Farah, Jr. · Director
  • Mitchell D. Kaye · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · broker-dealer Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AR, FL, IL, KS, NY, TX
  • Newport Coast Securities, Inc. (CRD 16944) · broker-dealer Newport Coast Securities, Inc. (CRD 16944) · New York, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Signed by David C. Cavalier, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 18, 2015. Read the notice at the SEC.

equity, optionsSEC
Feb 2013$4 MNo. 4$2 to $10 million

Aeolus Pharmaceuticals, Inc.: Raise no. 4, Feb 2013

Investors in this round

17 investors had bought by the notice of Mar 6, 2013: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • JOHN McMANUS · Executive Officer
  • Russell Skibsted · Executive Officer
  • Amit M. Kumar · Director
  • Chris A. Rallis · Director
  • David C. Cavalier · Director
  • John M. Farah, Jr. · Director
  • Joseph J. Krivulka · Director
  • Michael E. Lewis · Director
  • Peter D. Suzkak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Russell Skibsted, Senior Vice President & Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 6, 2013. Read the notice at the SEC.

equitySEC
Aug 2010$1 MNo. 3Under $2 million

Aeolus Pharmaceuticals, Inc.: Raise no. 3, Aug 2010

Investors in this round

2 investors had bought by the notice of Aug 19, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian L. Day · Executive Officer
  • John L. Mcmanus · Executive Officer
  • Amit L. Kumar · Director
  • Chris L. Rallis · Director
  • David L. Cavalier · Director
  • John L. Farah · Director
  • Joseph L. Krivulka · Director
  • Michael L. Lewis · Director
  • Peter L. Suzdak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John L. Mcmanus, President and ceo. Source: SEC Form D, newest notice filed Aug 19, 2010. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$3 MNo. 2$2 to $10 million

Aeolus Pharmaceuticals, Inc.: Raise no. 2, Oct 2009

Investors in this round

3 investors had bought by the notice of Aug 9, 2010: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian L. Day · Executive Officer
  • John L. Mcmanus · Executive Officer
  • Amit L. Kumar · Director
  • Chris L. Rallis · Director
  • David L. Cavalier · Director
  • John L. Farah · Director
  • Joseph L. Krivulka · Director
  • Michael L. Lewis · Director
  • Peter L. Suzdak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John L. Mcmanus, President and ceo. Source: SEC Form D and 2 amendments, newest notice filed Aug 9, 2010. Read the notice at the SEC.

equity, optionsSEC
Mar 2009$2 MNo. 1Under $2 million

Aeolus Pharmaceuticals, Inc.: Raise no. 1, Mar 2009

Investors in this round

2 investors had bought by the notice of Apr 6, 2009: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$525,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Brian Day · Executive Officer
  • John McManus · Executive Officer
  • Michael McManus · Executive Officer
  • Amit Kumar · Director
  • Chris Rallis · Director
  • David Cavalier · Director
  • John Farah · Director
  • Joseph Krivulka · Director
  • Michael Lewis · Director
  • Peter Suzdak · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael P. McManus, Chief Financial Officer, Treasurer and Secretary. Source: SEC Form D, newest notice filed Apr 6, 2009. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aeolus Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2015).

    SEC Form D · Dec 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2015

That is all the official record says: Aeolus Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aeolus Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aeolus Pharmaceuticals, Inc.
NameRoleNamed in
Brian DayExecutive officerDec 2015
David C. CavalierExecutive officerDec 2015
JOHN McMANUSExecutive officerDec 2015
Ken A. BrightExecutive officerDec 2015
Russell SkibstedExecutive officerMar 2013
Brian L. DayExecutive officerAug 2010
John L. McmanusExecutive officerAug 2010
Michael L. McmanusExecutive officerNov 2009
John McManusExecutive officerApr 2009
Michael McManusExecutive officerApr 2009
Amit A. KumarDirectorDec 2015
Chris A. RallisDirectorDec 2015
David C. CavalierDirectorDec 2015
Jeffrey A. ScottDirectorDec 2015
John M. ClericiDirectorDec 2015
John M. Farah, Jr.DirectorDec 2015
Mitchell D. KayeDirectorDec 2015
Amit M. KumarDirectorMar 2013
Joseph J. KrivulkaDirectorMar 2013
Michael E. LewisDirectorMar 2013
Peter D. SuzkakDirectorMar 2013
Amit L. KumarDirectorAug 2010
Chris L. RallisDirectorAug 2010
David L. CavalierDirectorAug 2010
John L. FarahDirectorAug 2010
Joseph L. KrivulkaDirectorAug 2010
Michael L. LewisDirectorAug 2010
Peter L. SuzdakDirectorAug 2010
Amit KumarDirectorApr 2009
Chris RallisDirectorApr 2009
David CavalierDirectorApr 2009
John FarahDirectorApr 2009
Joseph KrivulkaDirectorApr 2009
Michael LewisDirectorApr 2009
Peter SuzdakDirectorApr 2009